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pared all-cause utilization and costs associated with once-monthly paliperidone 
palmitate (PP) and oral atypical antipsychotics (OAT) in Medicaid and commercially-
insured schizoaffective disorder populations. METHODS: Adults with schizoaffec-
tive disorder and ≥ 2 claims for PP or OAT between 2009-2012 were identified in the 
MarketScan Medicaid and Commercial Databases, and followed 6 months before and 
12 months after initiating PP or OAT. Weighting and marginal structural modeling 
controlled for cohort differences and time-varying confounding to estimate patient-
month utilization and costs. RESULTS: Medicaid PP patients (n= 1320) were more 
likely male (53% vs. 42%, p< 0.05) and younger (mean age 38 vs. 40 years, p< 0.05) than 
OAT patients (n= 4216). Pre-index mood stabilizer use appeared similar for PP and 
OAT patients (55% vs. 53%, p= 0.42), but antidepressants were less common among PP 
patients (60 vs. 69%, p< 0.05). Risk of all-cause and mental health hospitalization and 
emergency department utilization was reduced (25.1%, 27.8%, 11.1% respectively, 
all p< 0.05) in patient-months with PP administration. Lower mean inpatient ($-185, 
95% confidence interval [CI] $-40-$-331) and outpatient ($-229, 95% CI $-69-$-389) 
costs in these months partially offset higher mean drug costs ($1136, 95% CI $1063-
$1209), reducing the modeled monthly cost differential associated with PP vs. OAT 
to $722 (95% CI $526-$917). Patient characteristics and utilization and cost trends 
for commercial PP (n= 167) and OAT (n= 2044) populations were similar to those 
observed in the Medicaid sample, although cost offsets did not reach statistical 
significance. CONCLUSIONS: Drug costs were higher in patient-months with PP 
administration; however, compared to patient-months without PP administration, 
there was a 25.1% reduction in all-cause hospitalization risk and a 24.1% reduction 
in inpatient costs.
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OBJECTIVES: While antidepressant medications constitute the mainstay of phar-
macologic management of MDD, patients with poor response are sometimes 
treated adjunctively with SGAs, such as aripiprazole, quetiapine, and olanzapine. 
This study estimated healthcare utilization and costs among patients with MDD 
initiating adjunctive therapy with SGAs, using a large US healthcare claims data-
base. METHODS: Adult patients receiving oral SGAs between 2009 and 2011 without 
evidence of schizophrenia or bipolar disorder were identified in the Truven MedStat 
MarketScan® Commercial Claims and Encounters and Medicare Supplemental and 
Coordination of Benefits Database. The “index date” was defined as the date of 
first receipt of an SGA. Patients with enrollment gaps during the 12-month period 
before the index date (pre-index period) or after the index date (follow-up period), 
no diagnosis of MDD during the pre-index period, no evidence of antidepressant 
medications overlapping their index date, or evidence of SGA prescriptions during 
the pre-index period were excluded. Healthcare utilization and costs were examined 
over the pre-index and follow-up periods. Healthcare encounters with diagnoses 
of MDD (ICD-9-CM 296.2, 296.3), and SGA and antidepressant prescriptions were 
designated “MDD-related”. RESULTS: A total of 17,697 patients met study criteria. 
The most frequently prescribed SGA was aripiprazole (56.3%), followed by quetia-
pine (34.3%), risperidone (13.4%), and olanzapine (7.8%). During the pre-index and 
follow-up periods, 27% and 7.5% of patients, respectively, were hospitalized for 
MDD (p< .0001), 37% and 20% were hospitalized for any reason (p< .0001), and 37% 
and 31% had ≥ 1 emergency department (ED) visits (p< .0001). Mean MDD-related 
total health care costs during the pre-index and follow-up periods were $5427 vs 
$6222, respectively (p< 0.0001). The average cost of SGAs during follow-up was 
$2154. CONCLUSIONS: Initiation of adjunctive therapy with SGAs in MDD patients 
is associated with a lower incidence of hospitalization (MDD-related and all-cause) 
and ED visits.
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OBJECTIVES: To evaluate healthcare resource utilization and costs among schizo-
phrenic patients who initiated typical and atypical long-acting injectables (LAIs) in 
the U.S. veteran population. METHODS: Using the Veterans Health Administration 
(VHA) Medical SAS datasets, patients with ≥ 1 pharmacy claim for LAIs were iden-
tified from 01OCT2005 through 30SEPT2012. The first LAI date was designated as 
the index date. Patients were required to be age ≥ 18 years, have continuous health 
plan enrollment for 12 months pre-index date and a schizophrenia diagnosis 
(International Classification of Diseases, 9th Revision, Clinical Modification [ICD-
9-CM] code 295.xx) during the study period. Patient data was observed until the 
earlier date of death or the end of the study period, and patients were assigned to 
typical LAI (fluphenazine, haloperidol, perphenazine) or atypical LAI (aripiprazole, 
olanzapine, paliperidone, risperidone) antipsychotic cohorts. All-cause (follow-up) 
and psychiatric disorder-related healthcare resource utilization and costs were 
assessed. Follow-up health care costs were adjusted to per-patient-per-month. 
The generalized linear model (GLM) was used to assess cost and utilization dif-
ferences among the cohorts. RESULTS: A total of 4,796 patients were identified 
(Typical LAI cohort: N= 1,941; Atypical LAI cohort: N= 2,855). Typical LAI patients 
were older (age 53.81 vs. 50.94 years, p< 0.0001) and more likely to be black (34.47% 
vs. 28.27%, p< 0.0001) than atypical LAI patients. After adjusting for baseline differ-
ences using GLM, more patients prescribed typical LAIs had all-cause emergency 
room [ER] visits (61.66% vs. 58.11%, p= 0.024) and inpatient stays (63.11% vs. 59.00%, 
p= 0.008) and psychiatric disorder-related ER visits (33.83% vs. 30.05%, p= 0.011) 
than those prescribed atypical LAIs. However, typical LAI patients incurred lower 
all-cause pharmacy ($197 vs. $433, p< 0.001), total ($2,850 vs. $3,073, p= 0.048) and 
psychiatric disorder-related total costs ($1,615 vs. $1,624, p= 0.908) than atypical LAI 
patients. CONCLUSIONS: Although patients who initiated typical LAIs had high 
healthcare resource utilization, their economic burden was lower compared to those 
who initiated atypical LAIs.
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OBJECTIVES: Clinical trial PSY-3012 was a randomized, multicenter, double-blind, 
parallel-group, relapse-prevention study of paliperidone palmitate 3-month injec-
tion (PP3M) versus placebo. Adults with schizophrenia received a once-monthly 
injection (PP1M) in an open-label (OL) 17-week transition phase, then a single PP3M 
injection for OL 12-week maintenance. Stabilized subjects were then randomized 
to PP3M or placebo in the double-blind (DB) phase. Exploratory objectives were 
to compare health resource utilization (HRU) and costs between PP3M and pla-
cebo. METHODS: HRU data were collected at the start of transition (OL baseline) 
and maintenance, at the end of open-label (DB baseline), and every 12 weeks 
during DB until end of study/early withdrawal. Information collected included 
hospitalizations, ER visits, day or night clinic stays, and outpatient treatment. 
Incidence rates (i.e., person-time) at OL baseline and during OL and DB phases 
were calculated for these resources. RESULTS: Overall, 145 subjects were ran-
domized to placebo and 160 subjects to PP3M during the DB phase. During the 
DB phase, incidence rate was < 1 event per person-year for all resources except 
outpatient treatment visits in both treatment groups and was higher for placebo 
than for PP3M. Hospitalizations with psychiatric and social reasons: incidence 
rate at baseline OL was similar between placebo and PP3M (0.51 vs. 0.58 hos-
pitalizations per person-year), decreased to comparable values during the OL 
phase (0.12 vs. 0.14 hospitalizations per person-year), and increased during the 
DB phase to 0.45 (placebo) and 0.15 (PP3M). Other HRU resources showed analo-
gous trends. CONCLUSIONS: During the DB phase, the incidence rate of HRU was 
numerically lower for PP3M than placebo. The incidence rate of most HRU was 
comparable between placebo and PP3M during the OL period, but increased more 
for placebo than for PP3M during the DB period. Ongoing analysis of the cost data 
will provide further insight into the economic impact of PP3M.
PMH28
tHe iMPaCt of anxiety on HealtHCare Utilization and Costs aMong 
resPondents froM tHe Co-Morbidities and syMPtoMs of dePression 
(Code) stUdy
Stephenson J.J.1, Grabner M.1, Faries D.2, Palli S.R.3, Robinson R.2
1HealthCore Inc., Wilmington, DE, USA, 2Eli Lilly, Indianapolis, IN, USA, 3CTI Clinical Trial & 
Consulting, Cincinnati, OH, USA
OBJECTIVES: To assess the impact of anxiety and of the depression-anxiety 
interaction on healthcare utilization and costs among patients with depres-
sion. METHODS: Survey-eligible adults with ≥ 2 medical claims for depression 
from 6/1/2009-5/31/2010 in the HealthCore Integrated Research Database were 
invited to participate in this retrospective/prospective study. Consenting respond-
ents completed index and 6-month surveys assessing health measures. Significant 
anxiety was classified into 4 categories (persistently anxiety free, persistent 
anxiety, resolving anxiety, and emerging anxiety) based on Generalized Anxiety 
Disorder (GAD-7) scores at both surveys. Respondents’ survey data were linked 
to 24-months of claims data (+12 months from index survey date). Mean annual 
post-index costs were compared using non-parametric bootstrapping adjusting 
for initial differences in demographics and health status using propensity score 
stratification. Similar models were created adding the interaction of remission 
status. RESULTS: Of 910 respondents with both surveys, 79.3% were female and 
mean (SD) age was 47.6 (11.4) years. Most respondents were persistently anxi-
ety free (52.9%), followed by persistent anxiety (23.4%), resolving anxiety (15.1%), 
and emerging anxiety (8.7%). Higher post-index all-cause healthcare costs were 
observed in respondents with persistent anxiety compared to others (combined 
group of resolving, emerging, or persistently anxiety-free) ($15,027 [$1,838] vs. 
$11,311 [$680], p= .0018). Persistent anxiety respondents had significantly higher 
mental health-related costs than persistently anxiety free respondents ($4,226 
[$551] vs. $3,044 [$332], p< .001). Respondents with anxiety and non-remitted 
depression had significantly higher all-cause and mental-health related costs 
vs. respondents without anxiety and non-remitted depression, with mean differ-
ences of $2,480 (95% CI: $337 to $4,685, p< .0001) and $789 (95% CI: $146 to $1,428, 
p< .0001), respectively. CONCLUSIONS: Respondents with a history of depression 
and persistent anxiety continue to have increased healthcare costs. Anxiety was 
a key factor irrespective of whether depression resolved. This study emphasizes 
the importance of treating patients to full resolution of all symptoms.
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OBJECTIVES: To examine differences in healthcare resource use (HRU) and cost 
among patients with schizophrenia initiating therapy with asenapine versus other 
branded atypical antipsychotics (“OBAP”) (i.e., aripiprazole, lurasidone, iloperidone, 
paliperodone). METHODS: Using two large US healthcare claims databases—one 
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of commercially insured patients aged < 65 years and one of Medicare enrollees—
we identified all adult patients (≥ 18 years) with schizophrenia (ICD-9-CM 295.
XX) initiating treatment with asenapine versus OBAP between 2009 and 2012. All 
patients were required to be continuously enrolled for the 6-month periods before 
and after the date of the first prescription claim for asenapine or OBAP (this was 
deemed the “index date”). We used propensity-score matching to control for dif-
ferences between the groups. Changes in HRU and costs (2012 dollars) between the 
6 month pre- and post-index periods were calculated within each group and then 
compared across groups. RESULTS: A total of 259 asenapine patients were propen-
sity matched to an equal number of OBAP patients; matched groups were similar 
in terms of age (mean: 39.9 years for asenapine patients vs. 41.8 years for OBAP 
patients, p= 0.19), gender (58.7% vs. 56.8% female; p= 0.66); and Charlson comor-
bidity index (mean: 0.47 vs. 0.52, p= 0.65). Differences in HRU between the pre- 
and post-index periods nominally favored asenapine patients, including greater 
reductions in admissions (mean: -0.49 for asenapine patients vs. -0.40 for OBAP 
patients, p= 0.38) and emergency room visits (-0.19 vs. -0.08, p= 0.26); decreases 
in total healthcare costs also favored asenapine patients ($-7,609 vs. $-5,585, 
p= 0.45). While pharmacy costs increased in both groups, the increase was signifi-
cantly lower among asenapine patients ($922 vs. $1,707, p< 0.05). CONCLUSIONS: 
Initiation of asenapine for schizophrenia is associated with significantly lower 
pharmacy costs than OBAP, and nominally greater decreases in levels of HRU and 
total healthcare costs.
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OBJECTIVES: Abuse of prescription opioid medications through tampering, such 
as the chewing or crushing of pills, is associated with greater healthcare use. 
This study was conducted to assess the economic cost of such tampering in the 
United States. METHODS: Participants from the US National Health and Wellness 
Survey were recontacted for an online survey assessing use, misuse, and abuse 
of prescription opioid medications. All measures were self-reported. Abuse was 
defined as taking prescription opioid medication for the purpose of getting high 
in the prior 3 months, and use of the medication in any form other than the 
original was considered tampering. Direct medical costs were estimated by apply-
ing unit costs to self-reported healthcare visits. Unit costs were sourced from 
the Truven Market Scan (TMS) database, and the analysis was repeated using 
unit costs from the Medical Expenditure Panel Survey (MEPS). Respondents who 
reported abuse of prescription opioids through tampering were compared to those 
who reported abuse without tampering. Costs were compared using bivariate 
statistics as well as generalized linear models (GLMs) to adjust for confound-
ers. RESULTS: Those who abused through tampering had significantly higher 
estimated healthcare costs during the 3-month recall period, with mean (unad-
justed) incremental cost of $18,814 using TMS unit costs (p< 0.001). This included 
higher mean costs for non-opioid-related medical visits ($11,944, p< 0.001), opi-
oid-related medical visits ($6,567, p< 0.001), and drug rehabilitation costs ($303, 
p< 0.001). Median total incremental costs were also higher by $3,803. GLMs indi-
cated increased total direct costs with tampering after adjusting for confound-
ers (p< 0.001). Conclusions were similar using MEPS unit costs. CONCLUSIONS: 
Tampering with prescription opioid medications in order to get high is associated 
with significantly increased medical costs compared to those who abuse with-
out tampering. Efforts to reduce tampering, such as the use of abuse-deterrent 
formulations of prescription opioid medications, may provide net healthcare 
savings.
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OBJECTIVES: To assess differences in healthcare costs associated with ini-
tiation of asenapine versus aripiprazole among patients with bipolar disorder 
(BD). METHODS: We used two large US healthcare claims databases that collec-
tively included commercially insured patients aged < 65 years and Medicare enroll-
ees to identify all adults (≥ 18 years) with BD (ICD-9-CM diagnosis codes 296.0X, 
296.1X, 296.4X, 296.6X, 296.7X, 296.80, 296.81, 296.89) who began therapy with 
asenapine or aripiprazole between 2009 and 2012. Patients without continuous 
enrollment for the 6-month periods before and after the date of the first prescrip-
tion claim for asenapine or aripiprazole (“index date”) were excluded. Asenapine 
patients were then matched to aripiprazole patients using propensity scoring to 
control for differences between the groups. HRU and associated costs (2012 dol-
lars) were deemed BD-related based on the presence of a BD diagnosis code on the 
relevant claim. Within each group, differences in BD-related HRU and costs were 
estimated between the pre- and post- index periods, and then compared across 
groups. RESULTS: A total of 2680 patients were included in the analyses (n= 1,340 
for each group); the groups were comparable with respect to age (mean age: 42.8 
years for asenapine patients vs. 42.2 years for aripiprazole patients, p= 0.27), per-
cent female (70.3% vs. 70.1%, p= 0.90), and Charlson comorbidity index (mean: 
0.45 vs. 0.42, p= 0.55). Asenapine patients had nearly a twofold greater decrease 
in total BD-related healthcare costs than aripiprazole patients (mean: -$863 for 
asenapine vs. -$490 for aripiprazole, p< 0.05); BD-related outpatient costs also 
exhibited a significant decrease ($-2 vs. a $10 increase for aripiprazole patients, 
p< 0.05). While pharmacy costs increased in both groups, the increase was signifi-
cantly lower among asenapine patients ($886 vs. $1,518, p< 0.05). CONCLUSIONS: 
As compared with aripiprazole, asenapine was associated with a reduction in 
total healthcare costs related to BD during the 6-month period following therapy 
initiation.
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OBJECTIVES: To estimate the national costs of prescription medications for child-
hood attention deficit hyperactivity disorder (ADHD) in the United States (U.S.) in 
2010 and to identify differences in diagnosis and costs by gender and racial/ethnic 
background. METHODS: To determine childhood ADHD diagnosis and prescription 
medication use, we used ICD-9 and drug ID codes recorded from pediatric visits in 
the 2010 National Ambulatory Medical Care Survey (NAMCS). Our analysis included 
all formulations of the following medications: amphetamine salts, atomoxetine, 
dextroamphetamine, dexmethylphenidate, and methylphenidate. To calculate the 
costs of medication use, we multiplied the 2010 average wholesale price (AWP) by a 
presumed usual number of yearly doses and weighed these costs to reflect national 
estimates. We compared differences in overall medication cost by gender and race 
using the student’s t test and evaluated differences in the proportion of patients 
diagnosed with ADHD using the chi-square test. RESULTS: Among pediatric visits in 
2010, we found that 5.70% (n= 7,201,548) were associated with a diagnosis of ADHD 
and, of those diagnosed, 67.29% (n= 4,846,163) had a mention of a prescribed ADHD 
medication. The nationally weighted sum of ADHD medication cost was $6.62 billion 
(mean= $1,336, SD= $1,220). Amphetamine salts prescriptions were associated with 
the highest overall cost ($3.67 billion). Overall drug expenditure did not differ by 
gender or race. We found a higher proportion of males were diagnosed with ADHD 
than females (7.97% vs. 3.48%, P < 0.001). Diagnosis with ADHD was less frequent 
among white children as compared with African-American children (5.79% vs. 7.09%, 
P = 0.012). CONCLUSIONS: We found that 5.70% of 2010 U.S. pediatric visits had a 
mention of ADHD diagnosis. We estimated that in 2010 U.S. expenditure for ADHD 
medications was $6.62 billion. Diagnosis of ADHD was more frequent among males 
and African-American children and less frequent among females and whites.
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OBJECTIVES: The rate of remission with treatment in major depressive disorder (MDD) 
is low; thus, switching medication is common. This study describes MDD patients in 
the US who switched to selected antidepressants; determines the rates of switching, 
discontinuation, and adherence; and quantifies the healthcare costs following treat-
ment switch. METHODS: Adults with ≥ 2 MDD-related claims (ICD-9 codes: 296.2x, 
296.3x) from the Truven Health Analytics MarketScan (1Q2001-4Q2012) database, who 
switched from an antidepressant to bupropion, citalopram, desvenlafaxine, dulox-
etine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, or 
vilazodone (index AD), were identified. The index date was the date of first treatment 
switch occurring on or after January 1, 2012. Continuous enrollment for ≥ 12 months 
prior to and ≥ 6 months following the index date was required. Patient and treatment 
characteristics during the 12-month baseline (i.e., pre-index) period are reported. 
Index antidepressant discontinuation (defined as a treatment gap of ≥ 45 consecutive 
days), adherence (defined as ≥ 80% of days covered with the index antidepressant), 
and switch rates (from the index antidepressant to another antidepressant) over 
the 6-month follow-up are reported. Healthcare costs incurred during the 6-month 
follow-up are also reported. RESULTS: 9,912 patients were included. On average, 
patients were 45.9 years old, and 72.7% were female. A mean of 1.9 antidepressants 
were prescribed during the baseline period. Patients had been on antidepressants for 
230.6 days, on average, at baseline. During the 6-month follow-up, 16.8% of patients 
switched treatment and 28.0% discontinued the index antidepressant. The proportion 
of adherent patients was 52.2%. Patients incurred an average total healthcare cost 
of $9,835 (2013 US$) during follow-up. CONCLUSIONS: Switching is prevalent, and 
a notable financial burden is observed among switchers in the US. Discontinuation 
rates are high, and adherence is suboptimal. Future research is warranted to deter-
mine which switching strategies are associated with optimal treatment and costs.
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OBJECTIVES: to determine the cost effectiveness of three treatment alternatives 
(medication, behavioral, and combined treatment of Atomoxetine and behavioral 
therapy) for attention deficit hyperactivity disorder in children from payer per-
spective with time horizon: 12 weeks METHODS: a prospective trial based eco-
nomic evaluation was conducted on children in psychiatric out patients clinic at 
Abasseya Mental Hospital (AMH), Cairo ,Egypt who are 6 to 12 years of age (boys or 
girls), and had a clinical diagnoses of ADHD as defined in the Diagnostic and sta-
tistical Manual fourth edition (DSM_IV). Patients were classified into three groups: 
(Depended on psychiatric recommendation and parents preferences) medication 
only group (group I), behavioral therapy group (group II), and combined medication 
and behavioral therapy group (group III). Each treatment had both a cost and an 
outcome associated with it. Cost effectiveness ratio comprising the average total 
cost per child per unit of outcome three months-Quality Adjusted Life Years “QALY” 
in each of the three groups. RESULTS: The combined therapy was associated with 
the highest cost effective ratio C/E Ratio of 7695.524 LE per QALY, medication therapy 
was 4381.927 LE per QALY, While C/E Ratio of behavioral therapy was 3337.339 LE 
per QALY. According to base-case analysis, combined therapy resulted in greatest 
health benefits but at the same time it was the most expensive treatment option. 
Behavioral therapy was the least effective and cheapest option. The sensitivity anal-
